| Document |
Document Title |
|
WO/2014/169710A1 |
The present description describes the molecular structure of (aminophenyl-amino)-pyramidyl benzamide, method of synthesis thereof, and a method for using the compound to inhibit kinase, and treatment of diseases related to B cells.
|
|
WO/2014/169167A1 |
The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/E...
|
|
WO/2014/162122A1 |
There is provided a compound of formula (I), which compound has antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the S...
|
|
WO/2014/163161A1 |
The present invention pertains to a compound indicated by formula (I), said compound being useful as a prophylactic or treatment agent for epilepsy and neurodegenerative diseases, etc. In the formula (I), each symbol is as defined in the...
|
|
WO/2014/164678A1 |
Radiolabeled 4-phenylquinazoline-2-carboxamides useful as imaging agents for positron emission tomography of translocator protein (TSPO) are described. Methods of detecting TSPO and neuroinflammation using the compounds are described. Al...
|
|
WO/2014/162126A1 |
There are provided compounds of formula I, wherein R1A to R1E, R2 to R5, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the fam...
|
|
WO/2014/154856A1 |
The present invention relates to unsaturated amine salts of HMG-CoA reductase inhibitors, to a method of producing said amine salts and to the use of said amine salts in the production of pharmaceutically acceptable salts of HMG-CoA redu...
|
|
WO/2014/160521A1 |
Compounds having structural formula (I) : or a pharmaceutically acceptable salt or a tautomer thereof or having structural formula (III) : or a pharmaceutically acceptable salt or tautomer thereof useful for treating disorders related to...
|
|
WO/2014/155304A1 |
The present invention relates to a new synthetic intermediate, namely the compound of formula I-2 I or a salt thereof. Said compound of formula I-2 or its salt can be used to prepare the compound of formula I-3 I which is an important sy...
|
|
WO/2014/154857A1 |
The present invention relates to oxygen-comprising amine salts of HMG-CoA reductase inhibitors, to a method of producing said amine salts and to the use of said amine salts in the production of pharmaceutically acceptable salts of HMG-Co...
|
|
WO/2014/157216A1 |
The present invention addresses the problem of providing a photoelectric conversion material well-suited for continuous evaporation, a photoelectric transducer in which the photoelectric conversion material is used, a method for using th...
|
|
WO/2014/152768A1 |
The present invention provides processes for the preparation of cyclohexanediamine compounds of formula Ia and intermediates thereof. The compounds are useful as Syk kinase inhibitors and in various pharmaceutical compositions, and parti...
|
|
WO/2014/151616A1 |
The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharma...
|
|
WO/2014/152716A1 |
Disclosed herein are pyrimidinediamine compounds of formula I and formula II and methods for treating or preventing a viral infection, such as infections caused by dengue virus, in a subject comprising administering to said subject an ef...
|
|
WO/2014/150677A1 |
There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, vi...
|
|
WO/2014/146581A1 |
The present invention relates to a method for preparing an acrylate compound. The acrylate compound has a structure as shown in general formula (I). The method includes: subjecting a compound with a structure of general formula (II) or a...
|
|
WO/2013/164337A9 |
The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein the integers are as defined in the description. The claimed compounds are useful for the treatment of a bacterial infe...
|
|
WO/2014/140246A1 |
The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula I as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are suit...
|
|
WO/2014/145807A1 |
Processes for the preparation of 4-amino-1-((1 S,4R,5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-
enyl)-lH-pyrimidin-2-one (13, RX-3117) and its intermediates are described.
|
|
WO/2014/144169A1 |
Provided herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, R1, R1a, R2a, R2b, R2c, R2d, are as defined herein, and Ring HET is a 6-membered monocyclic h...
|
|
WO/2014/145004A1 |
Compounds useful in the treatment of mammalian cancers and especially human cancers according to Formula I are disclosed. Formula (I). Pharmaceutical compositions and methods of treatment employing the compounds disclosed herein are also...
|
|
WO/2014/142255A1 |
Provided is a heterocyclic compound exhibiting an RORĪ³t-inhibiting action. Specifically provided is a compound represented by formula (I) or a salt thereof. [In the formula, Ar indicates partial formulas (1) through (5), Q indicates a b...
|
|
WO/2014/139086A1 |
The present invention relates to the field of chemical synthesis, and discloses a preparation method of ambrisentan. In the preparation method, using (S)-phenethylamine as a resolving agent, to form two diastereomers with 2-[(4,6-dimethy...
|
|
WO/2014/139489A1 |
A method for the preparation of ticagrelor of formula I, wherein the key reaction of the entire synthesis is condensation of an amino cyclopentane diol with pyrimidine, providing the isolated intermediate of formula IV. The amino cyclope...
|
|
WO/2014/139465A1 |
The present invention relates to novel pyrimidine and pyridine compounds of formula (I) or a pharmaceutical acceptable salt thereof, wherein R1, R2, R3, R4, R5, X, Y and G are as defined in the description, to pharmaceutical compositions...
|
|
WO/2014/139087A1 |
Provided is a racemization method of a chiral 2-[(4,6-dimethylpyrimidine-2-yl)oxy]-3-methoxy-3,3-diphenyl propionic acid, comprising the following steps: adding a 2-[(4,6-dimethylpyrimidine-2-yl)oxy]-3-methoxy-3,3-diphenyl propionic acid...
|
|
WO/2014/138302A1 |
A new class of antibiotics effective against methicillin-resistant Staphylococcus aureus (MRSA) is disclosed. Compounds of this class can impair cell-wall biosynthesis by binding to both the allosteric and the catalytic domains of penici...
|
|
WO/2014/138053A1 |
In one aspect, the invention relates to compounds having the formula: (I) where R1-R5 and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In anoth...
|
|
WO/2014/135955A1 |
The present disclosure provides substituted pyrimidine carboxamides of Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein A1, X, A2, W1, W2, W3, E, Z, and R4 are defined as set forth in the specification....
|
|
WO/2014/068588A9 |
The invention discloses the synthesis of Etravirine via intermediate 4-((4-amino-5-bromo-6-chloropyrimidin-2-yl) amino)benzonitrile and process for the preparation of Etravirine of the formula-I.
|
|
WO/2014/135414A1 |
This invention relates to substituted bicyclic dihydropyrimidinones of formula (1) and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for ...
|
|
WO/2014/133020A1 |
In the present invention, an agent for preventing and treating respiratory disease comprises the compound represented by formula (I), a salt thereof, or a hydrate of the same, and can be used for the prevention and treatment of a respira...
|
|
WO/2014/127881A1 |
The invention relates to compositions of formula (I), and in particular drugs containing at least one composition of formula (I) for use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions triggered ...
|
|
WO/2014/129048A1 |
An anthracene derivative which is characterized by being represented by formula (1). (In formula (1), at least one of Ar1, Ar2, Ar3, L1, L2 and L3 is a group derived from a skeleton represented by formula (10).)
|
|
WO/2014/128189A1 |
This invention relates to 2-aminopyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.
|
|
WO/2014/129431A1 |
The invention provides a drug having as the active ingredient a compound having Trk-inhibiting activity in the prevention and/or treatment of Trk-associated diseases, for example, pain, pruritus, lower urinary tract disorders, asthma, al...
|
|
WO/2014/128719A2 |
The present disclosure relates to a process for the preparation of Bispyribac-sodium by condensing 2,6-dihydroxy benzoic acid with 2-(alkyl sulfonyl)-4,6-dialkoxy pyrimidine in the presence of at least one base and at least one solvent. ...
|
|
WO/2014/129268A1 |
Provided are: a liquid crystal compound satisfying at least one property such as high stability to light, high clearing point, low minimum temperature of the liquid crystal phase, low viscosity, suitable optical anisotropy, large dielect...
|
|
WO/2014/125911A1 |
Provided are: a liquid-crystalline compound which satisfies at least one property selected from high stability to light, a high clear point, a low lower-limit temperature of a liquid crystal phase, a low viscosity, proper optical anisotr...
|
|
WO/2014/124915A1 |
The present invention relates to a process for preparing alkaline earth metal-complexed metal bisamides of the formula (I) from metal monoamides of the formula (II). The present invention further relates to a process for preparing alkali...
|
|
WO/2014/122160A1 |
This invention relates to substituted bicyclic dihydropyrimidinones of formula (I) and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for ...
|
|
WO/2014/122267A1 |
The present invention belongs to the field of EP4 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP4 receptor. The invention also refers to the process for ...
|
|
WO/2014/123392A1 |
The present specification provides an organic light-emitting element comprising an organic material layer consisting of one or more layers, including a heterocyclic compound, a first electrode, a second electrode, and a light-emitting la...
|
|
WO/2014/118737A1 |
The present invention provides erlotinib saccharinate and erlotinib maleate or hydrates thereof, their crystalline forms, processes for their preparation, and pharmaceutical compositions thereof.
|
|
WO/2014/117948A1 |
The invention relates to novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular ...
|
|
WO/2014/117947A1 |
The invention relates to novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular ...
|
|
WO/2014/114274A1 |
The present invention relates to a deuterated phenyl amino pyrimidine compound and pharmaceutical composition containing the same. Specifically provided are a deuterated phenyl amino pyrimidine compound as represented by formula (I), and...
|
|
WO/2014/113859A1 |
The present invention relates to 2-chloro-4-anilino-quinazoline derivatives with EGFR and/or VEGFR-2 protein tyrosine kinase inhibiting activity, to anti-tumour pharmaceutical compositions that comprise said compounds, and to methods for...
|
|
WO/2014/107622A1 |
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.
|
|
WO/2014/106762A1 |
The present invention relates to 4-pyrimidinylamino-benzenesulfonamide derivatives of general formula (I) and pharmaceutically acceptable salts, solvates, hydrates, regioisomeric and polymorphic forms thereof, processes for manufacturing...
|
